Drugs / AG-636
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03834584 | May 2019 → Jun 2020 | lymphoma | Agios Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-11-06 | Agios Pharmaceuticals, Inc. | Results Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting agios.com ↗
Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG -636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-11-06 | Agios Pharmaceuticals, Inc. | Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting agios.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-636 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03834584 ↗ |
| Action | Inhibit | “DHODH) inhibitor” NCT03834584 ↗ |
| Modality | Small molecule | “oral Dihydroorotate Dehydrogenase (DHODH) inhibitor” NCT03834584 ↗ |
| Route | Oral | “administered orally” NCT03834584 ↗ |
| Target | DHODH | “Dihydroorotate Dehydrogenase (DHODH) inhibitor” NCT03834584 ↗ |